OTHER × Cyclophosphamide × Lymphoid × Clear all
NCT02727803 2026-05-22

Personalized NK Cell Therapy in CBT

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
NCT01962636 2026-05-20

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase NA Terminated
200 enrolled
NCT03246906 2026-05-14

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Fred Hutchinson Cancer Center

Phase 2 Terminated
150 enrolled 18 charts
NCT03779854 2026-05-14

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Recruiting
68 enrolled
NCT05092451 2026-05-06

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
80 enrolled
NCT00641381 2026-05-04

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

City of Hope Medical Center

Phase 1 Completed
25 enrolled
NCT03670966 2026-05-04

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
30 enrolled